论文部分内容阅读
目的探讨Ⅰ类MHC链相关蛋白(MICA)在妇科恶性肿瘤中的表达,并分析其与临床病理参数的关系及临床应用价值。方法用ELISA法对58名确诊妇科恶性肿瘤患者和98名体检健康者进行血清可溶性MICA(sMICA)浓度检测,分析其表达水平与肿瘤病理参数间关系。用ROC曲线对sMICA结果进行分析与评价。结果妇科恶性肿瘤患者血清中sMICA水平为0.79(0.52,1.28)ng/mL,对照组为为0.32(0.18,0.47)ng/mL,两者具有显著性差异(U=-0.673,P<0.01)。除FIGO分期Ⅲ～Ⅳ期组患者血清sMICA水平与Ⅰ～Ⅱ期组相比有统计学差异(U=1.98,P≤0.05)外,疾病类型、肿瘤浸润程度、肿瘤分化程度及组织类型各组间无显著性差异(P>0.05)。临界值为0.302 ng/mL时,对妇科恶性肿瘤诊断的ROC曲线下面积(AUCROC)为0.816,敏感性为0.847,特异性为0.718。结论血清中sMICA表达水平与妇科恶性肿瘤的发生密切相关,以sMICA 0.302 ng/mL为临界值,有助于妇科恶性肿瘤的诊断。
Objective To investigate the expression of MHC class I related protein (MICA) in gynecologic malignancies and analyze its relationship with clinicopathological parameters and its clinical value. Methods Serum soluble MICA (sMICA) was detected by ELISA in 58 patients diagnosed with gynecological malignant tumors and 98 healthy controls. The relationship between the expression levels and tumor pathological parameters was analyzed. The results of sMICA were analyzed and evaluated by ROC curve. Results The levels of sMICA in serum of gynecological malignant tumor patients were 0.79 (0.52,1.28) ng / mL and 0.32 (0.18,0.47) ng / mL respectively, with significant difference (U = -0.673, P <0.01) . In addition to the serum levels of sMICA in patients with FIGO stage Ⅲ ~ Ⅳ were significantly higher than those in patients with stage Ⅰ ~ Ⅱ (U = 1.98, P≤0.05), the type of disease, the degree of tumor infiltration, the degree of tumor differentiation and the type of tissue There was no significant difference (P> 0.05). The area under the ROC curve (AUCROC) for the diagnosis of gynecological malignancies at a cutoff of 0.302 ng / mL was 0.816 with a sensitivity of 0.847 and a specificity of 0.718. Conclusion The expression level of sMICA in serum is closely related to the occurrence of gynecologic malignancies. The critical value of sMICA 0.302 ng / mL is helpful to the diagnosis of gynecologic malignancies.